Quest Diagnostics Incorporated (NYSE:DGX) Receives Average Recommendation of “Hold” from Brokerages

Shares of Quest Diagnostics Incorporated (NYSE:DGXGet Rating) have earned an average rating of “Hold” from the fourteen ratings firms that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $150.92.

A number of brokerages have recently commented on DGX. Morgan Stanley lowered their target price on Quest Diagnostics from $159.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Monday, February 14th. Bank of America lowered their price target on Quest Diagnostics from $166.00 to $163.00 and set a “buy” rating on the stock in a research report on Friday, April 22nd. Truist Financial lowered their price target on Quest Diagnostics from $170.00 to $160.00 in a research report on Wednesday, January 19th. Citigroup downgraded Quest Diagnostics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $175.00 to $140.00 in a research report on Monday, April 4th. Finally, UBS Group increased their price target on Quest Diagnostics from $139.00 to $150.00 in a research report on Sunday, April 24th.

In related news, SVP Michael E. Prevoznik sold 6,228 shares of the stock in a transaction that occurred on Tuesday, March 8th. The stock was sold at an average price of $135.21, for a total value of $842,087.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Catherine T. Doherty sold 2,750 shares of the stock in a transaction that occurred on Thursday, February 24th. The shares were sold at an average price of $126.26, for a total value of $347,215.00. The disclosure for this sale can be found here. Company insiders own 1.45% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Signaturefd LLC increased its stake in Quest Diagnostics by 7.5% during the fourth quarter. Signaturefd LLC now owns 1,064 shares of the medical research company’s stock worth $184,000 after acquiring an additional 74 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Quest Diagnostics by 1.0% in the third quarter. Daiwa Securities Group Inc. now owns 7,499 shares of the medical research company’s stock valued at $1,090,000 after buying an additional 76 shares in the last quarter. MMA Asset Management LLC grew its stake in shares of Quest Diagnostics by 4.8% in the fourth quarter. MMA Asset Management LLC now owns 1,695 shares of the medical research company’s stock valued at $293,000 after buying an additional 78 shares in the last quarter. Farmers & Merchants Investments Inc. grew its stake in shares of Quest Diagnostics by 2.1% in the fourth quarter. Farmers & Merchants Investments Inc. now owns 3,904 shares of the medical research company’s stock valued at $675,000 after buying an additional 79 shares in the last quarter. Finally, Strs Ohio grew its stake in shares of Quest Diagnostics by 0.5% in the fourth quarter. Strs Ohio now owns 17,500 shares of the medical research company’s stock valued at $3,027,000 after buying an additional 79 shares in the last quarter. 86.45% of the stock is owned by institutional investors.

Shares of DGX opened at $135.83 on Friday. Quest Diagnostics has a 52 week low of $125.77 and a 52 week high of $174.16. The company has a quick ratio of 1.44, a current ratio of 1.46 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $15.94 billion, a price-to-earnings ratio of 9.04 and a beta of 1.12. The stock’s 50-day moving average price is $137.41 and its 200-day moving average price is $144.81.

Quest Diagnostics (NYSE:DGXGet Rating) last issued its earnings results on Thursday, April 21st. The medical research company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $2.92 by $0.30. Quest Diagnostics had a return on equity of 27.08% and a net margin of 17.61%. The firm had revenue of $2.61 billion for the quarter, compared to the consensus estimate of $2.64 billion. During the same quarter in the prior year, the business earned $3.76 earnings per share. The company’s revenue was down 4.0% compared to the same quarter last year. As a group, equities analysts anticipate that Quest Diagnostics will post 9.27 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 20th. Stockholders of record on Wednesday, April 6th were given a $0.66 dividend. This represents a $2.64 annualized dividend and a dividend yield of 1.94%. The ex-dividend date of this dividend was Tuesday, April 5th. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.62. Quest Diagnostics’s dividend payout ratio (DPR) is 17.58%.

Quest Diagnostics Company Profile (Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.